Immunoprecise Current Assets vs Total Assets Analysis

IPA
 Stock
  

USD 5.59  0.73  11.55%   

Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Current Assets and its Total Assets accounts. Please see Risk vs Return Analysis.

Current Assets vs Total Assets

Current Assets vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Current Assets account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Immunoprecise Antibodies' Current Assets and Total Assets is 0.91. Overlapping area represents the amount of variation of Current Assets that can explain the historical movement of Total Assets in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Current Assets and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Assets of Immunoprecise Antibodies are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Current Assets i.e., Immunoprecise Antibodies' Current Assets and Total Assets go up and down completely randomly.

Correlation Coefficient

0.91
Relationship DirectionPositive 
Relationship StrengthVery Strong

Current Assets

Current assets of Immunoprecise Antibodies include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Immunoprecise Antibodies. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Total Assets

Total assets refers to the total amount of Immunoprecise Antibodies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunoprecise Antibodies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; Tax Assets and Trade and Non Trade Receivables.
Most indicators from Immunoprecise Antibodies fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.Immunoprecise Antibodies Selling General and Administrative Expense is projected to increase significantly based on the last few years of reporting. The past year's Selling General and Administrative Expense was at 8.53 Million. The current year Issuance Purchase of Equity Shares is expected to grow to about 4 M, whereas Net Cash Flow Business Acquisitions and Disposals is forecasted to decline to (3.8 M).
 2019 2020 2021 2022 (projected)
Interest Expense537 K517 K334 K365.43 K
Gross Profit8.03 M11.54 M10.98 M10.97 M

Immunoprecise Antibodies fundamental ratios Correlations

0.910.870.9-0.25-0.730.320.51.00.841.00.890.890.850.620.920.990.820.70.830.87
0.910.591.0-0.08-0.950.60.510.940.540.880.740.740.570.270.690.860.890.750.980.62
0.870.590.56-0.39-0.31-0.090.370.841.00.910.860.860.980.90.980.920.550.470.440.97
0.91.00.56-0.11-0.960.590.470.920.520.860.70.70.530.220.660.840.870.720.990.59
-0.25-0.08-0.39-0.11-0.050.710.68-0.25-0.44-0.250.080.08-0.22-0.21-0.21-0.240.320.510.01-0.41
-0.73-0.95-0.31-0.96-0.05-0.74-0.46-0.77-0.25-0.68-0.53-0.53-0.290.04-0.43-0.65-0.84-0.7-0.99-0.35
0.320.6-0.090.590.71-0.740.730.35-0.160.270.380.380.0-0.230.110.260.770.790.69-0.09
0.50.510.370.470.68-0.460.730.490.320.520.780.780.530.430.550.530.850.950.510.38
1.00.940.840.92-0.25-0.770.350.490.80.990.870.870.810.570.890.980.830.70.860.84
0.840.541.00.52-0.44-0.25-0.160.320.80.880.820.820.970.90.960.890.480.410.390.97
1.00.880.910.86-0.25-0.680.270.520.990.880.920.920.890.690.951.00.810.70.780.91
0.890.740.860.70.08-0.530.380.780.870.820.921.00.920.790.950.930.860.850.650.86
0.890.740.860.70.08-0.530.380.780.870.820.921.00.920.790.950.930.860.850.650.86
0.850.570.980.53-0.22-0.290.00.530.810.970.890.920.920.940.990.910.620.590.430.96
0.620.270.90.22-0.210.04-0.230.430.570.90.690.790.790.940.870.710.370.40.120.89
0.920.690.980.66-0.21-0.430.110.550.890.960.950.950.950.990.870.960.70.650.560.96
0.990.860.920.84-0.24-0.650.260.530.980.891.00.930.930.910.710.960.80.70.760.91
0.820.890.550.870.32-0.840.770.850.830.480.810.860.860.620.370.70.80.970.880.57
0.70.750.470.720.51-0.70.790.950.70.410.70.850.850.590.40.650.70.970.750.49
0.830.980.440.990.01-0.990.690.510.860.390.780.650.650.430.120.560.760.880.750.49
0.870.620.970.59-0.41-0.35-0.090.380.840.970.910.860.860.960.890.960.910.570.490.49
Click cells to compare fundamentals

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies Implied Volatility

    
  347.26  
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
157.3 M
Quarterly Revenue Growth YOY
0.074
Return On Assets
-0.13
Return On Equity
-0.25
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.